Absci (ABSI) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.19

Estimate

-$0.20

Surprise

+3.9%

Revenue (period 2026-09-30)

$304,000

Score today

4.7/10

Revenue source: xbrl.

Absci (ABSI) reported a narrower loss than forecast — adjusted EPS of -$0.19 against the -$0.20 estimate (a 3.9% beat on a still-unprofitable quarter).

• Needham Maintains Buy on Absci, Raises Price Target to $15 — benzinga, 2026-11-13
• Absci Q3 2026 Earnings Call Transcript — benzinga, 2026-11-12
• Absci Corporation Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12

TrendMatrix currently rates ABSI Sell at 4.7/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a -8.0% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$9.13

Price target

$12.89

Stop

$8.50

Upside to target

+41.1%

Reward-to-risk

2.7:1

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.57B

P/E (fwd)

-13.3

52-week range

$2.24–$12.54

Off 52-week high

27.2%

RSI (14)

50

Volume vs avg

1.20×

Score today

4.7/10